Cyxone
0,04 SEK +2,56%Vær den første som følger denne virksomhed
Cyxone is a biotechnology company. The company's specialist expertise is found in the development of pharmaceuticals with a focus on plant protein as a base. The pharmaceutical is intended to be used mainly in the treatment of immune-related diseases, and the products are based on cyclotide technology. The purpose is that the pharmaceutical will be used in the treatment of multiple sclerosis and rheumatoid arthritis. Cyxone's head office is located in Malmö.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
CYXO
Daglig lav / høj pris
0,039 / 0,041
SEK
Markedsværdi
15 mio. SEK
Aktieomsætning
6,78 t SEK
Volumen
174 t
Seneste videoer
Finanskalender
Delårsrapport
07.11.2024
Årsrapport
25.02.2025
Større aktionærerKilde: Millistream Market Data AB
| Ejer | Kapital | Stemmer |
|---|---|---|
| Avanza Pension | 5,8 % | 5,8 % |
| Ivar Nordqvist | 4,2 % | 4,2 % |
| Oxy Pharma AB | 2,8 % | 2,8 % |
| ABBMO Holding AB | 2,4 % | 2,4 % |
| UBS Switzerland AG | 2,3 % | 2,3 % |
| Christian Pettersson | 2,1 % | 2,1 % |
| Göran Ofsén | 1,9 % | 1,9 % |
| Nordnet Pensionsförsäkring | 1,8 % | 1,8 % |
| Nordnet Livsforsikring AS | 1,3 % | 1,3 % |
| Clearstream Banking SA | 1,2 % | 1,2 % |
ViserAlle indholdstyper
Cyxone AB publishes outcome of rights issue
The subscription period in Cyxone's rights issue starts today
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools